Gynecologic Cancers
A gynecological cancer diagnosis can be life-altering. At City of Hope, our dedicated team of experts takes an integrated, patient-centered approach to diagnose and treat ovarian, cervical, uterine (endometrial), vaginal, vulvar and fallopian tube cancers.
By working collaboratively, our clinicians and researchers transform innovative scientific discoveries into promising new treatments that are more effective against cancer with fewer side effects for the patient.
At City of Hope, our team of experts uses leading-edge methods to treat gynecologic cancers, including cervical cancer, ovarian cancer and uterine (endometrial) cancer.
Our patients have access to a wide variety of gynecologic cancer clinical trials, including new therapies, surgical techniques, radiation approaches, and prevention strategies.
City of Hope is a nationally recognized leader in gynecological cancer research. We offer access to promising treatments for cervical cancer, ovarian cancer and uterine (endometrial) cancer that are not readily available elsewhere.
When you come to City of Hope, you automatically gain access to an unparalleled array of support services to help you and your family take during and after your gynecologic cancer treatment.
- We have advanced imaging technologies that can accurately pinpoint a tumor’s size, shape and location, enhancing our doctors’ detection and treatment planning capabilities.
- Minimally-invasive and robotically-assisted surgical techniques that can offer optimal outcomes with less pain, reduced scarring and faster healing time.
- Cytoreductive (tumor debulking) procedures can enhance radiation and chemotherapy responses and improve outcomes for early- and advanced-stage cancer patients.
- Targeted radiation regimens that are sculpted to the size and shape of the tumor, focusing its impact on cancer cells while minimizing exposure to nearby normal tissues.
- Specialization in heated intraperitoneal chemotherapy (HIPEC) that applies cancer drugs directly in the abdominal cavity instead of orally or through the bloodstream. This can increase the drugs’ effectiveness and improve outcomes.
- Our drug development pipeline quickly identifies new cancer drugs and turns them into promising therapies for clinical trials.
- Fertility-preserving options for younger patients who want to have children after cancer treatment.
- All gynecologic cancer patients can participate in our survivorship program after their treatment completes. Our doctors and researchers are working to develop resources to help improve the quality of life for survivors, and all patients can participate in ongoing long-term research related to their life after cancer.
Additionally, City of Hope patients have access to our extensive team of supportive care experts, who will help you and your caregivers achieve and maintain a better quality of life during and after your cancer treatment.
City of Hope is one of the few facilities designated a comprehensive cancer center by the National Cancer Institute.
Our developments in the areas of breakthrough cancer drugs, bone marrow transplants and CAR T cell therapy are recognized internationally.
Our leadership in research and innovation continually enhances our ability to provide novel and differentiated approaches to cancer care.
Joshua G. Cohen, M.D., F.A.C.O.G., F.A.C.S., is a board-certified gynecologic oncologist dedicated to offering his patients in Orange County empathy and excellence in clinical care.
Maria de Leon, M.D., is an assistant clinical professor in City of Hope's Division of Gynecologic Oncology, specializing in diagnosis and treatment of cervical, endometrial/uterine and ovarian cancers.
Thanh H. Dellinger, M.D., is a gynecologic oncologist focusing on ovarian cancer, cervical cancer, uterine cancer, robotic surgery and fertility sparing cancer treatments.
Amy Hakim, M.D., is a surgical oncologist dedicated to treating gynecological cancers. In addition to providing gynecological surgery options to treat cancer, Dr. Hakim is also studying the connection these cancers’ connection to then human papillomavirus (HPV) and the HPV vaccine.
Yi-Jen Chen, M.D., Ph.D., is a radiation oncologist specializing in gastrointestinal cancers, gynecological cancers and esophageal cancers.
Scott Glaser, M.D., is a radiation oncologist and an assistant professor of radiation oncology at City of Hope.
Edward Wenge Wang, M.D., Ph.D., is the section chief of the Gynecologic Oncology and assistant professor in the Department of Medical Oncology & Therapeutics Research.
Dr. Burton’s specialties include male and female voiding dysfunction, incontinence, benign prostatic hyperplasia, bladder neck obstruction, bladder and uterovaginal prolapse, rectocele, female genitourinary reconstruction, urethral diverticulum and urinary tract fistula.
Christopher Chung, M.D., is a urogynecologist and an associate clinical professor in the Division of Gynecologic Oncology. He sees patients in Duarte and Arcadia, California.
